|
 |
|
< back /
| 8:30 |
Welcome |
Anatoly Langer, MD |
|
8:35
 |
New Initiatives To Improve Care: Patient Empowerment |
Anatoly Langer, MD |
8:55
 |
What Every Physician Needs to Know About Drug Interaction |
Peter Lin, MD |
9:15
 |
Innovations in Hypertension Management: Direct rennin inhibition |
David Fitchett, MD |
9:35
 |
Managing CV Risk in Patients With Diabetes |
Philip McFarlane, MD |
| 9:55 |
Panel Discussion |
All faculty |
| 10:25 |
Break |
|
|
10:45
 |
Why We Hate Coumadin |
Peter Lin, MD |
11:05
|
Managing ACS Patients: Importance of dual antiplatelet therapy |
David Fitchett, MD |
11:25
|
Evolution of Statin Trials On Vulnerable Plaque |
Jacques Genest, MD |
11:45
 |
Better BP Control: The earlier the better |
Philip McFarlane, MD |
| 12:05 |
Panel Discussion |
All faculty |
| 12:35 |
Lunch |
|
|
13:30
 |
|
Christian Constance, MD |
13:50
|
Why Do We Go So Low and How Do We Achieve Aggressive Goals? |
Marc-André Lavoie, MD |
14:10
 |
The Role of ACE-I: Managing risk across the CV continuum |
David Fitchett, MD |
14:30
 |
Exploration of landmark CV trials: HOPE to ONTARGET |
Christian Constance, MD |
| 14:50 |
Panel Discussion |
All faculty |
| 15:20 |
Close |
|
|
|
 |
|